By Evan Chait, PT, LAc
Educational content only. This article does not provide medical advice, diagnosis, or treatment, and it is not guidance on obtaining, dosing, or using any compound. Neither substance discussed here is an FDA-approved medication.
CJC-1295 and ipamorelin are the most frequently discussed pairing in peptide therapy, and the most frequently misrepresented. The mechanism is genuinely interesting. The evidence is thinner than the marketing suggests. The regulatory position is unsettled and has moved repeatedly.
All three of those things are true at once, and a useful article has to hold them together rather than pick one.
What each compound is
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, derived from the biologically active GHRH(1-29) fragment. It acts on GHRH receptors on the anterior pituitary, where its effect is to extend the amplitude of growth hormone pulses.
It exists in two forms that are often conflated and behave quite differently. The form without a drug affinity complex, sometimes called modified GRF(1-29), has a short plasma half-life on the order of half an hour. The form with a drug affinity complex binds albumin and has a substantially longer half-life. These are not interchangeable, and a discussion that does not specify which form it means is not a precise discussion.
Ipamorelin acts on a different receptor entirely: the ghrelin receptor, GHSR-1a. Activation there triggers the initiation of a growth hormone pulse. Ipamorelin is generally described as relatively selective within its class, which is the basis for the claim that it produces less effect on other pituitary hormones than some older secretagogues.
Why they are paired
The rationale is mechanistically coherent, and worth understanding because it is the strongest part of the case.
Growth hormone is released in pulses, and two separate control systems govern those pulses. GHRH signalling influences how large a pulse is. Ghrelin receptor signalling influences whether a pulse is initiated. Acting on both simultaneously is therefore not redundant, and co-activation produces greater pulse amplitude than either pathway alone in preclinical models.
There is a second argument sometimes made: that because these compounds work through the pituitary rather than supplying growth hormone directly, the body’s own feedback mechanisms remain in the loop. This is a reasonable distinction from exogenous growth hormone administration, though it should not be over-read. Feedback intact is not the same as feedback unaffected.
What the human evidence does and does not show
This is where the gap opens.
For CJC-1295 individually, published human pharmacology exists. A single-dose study reported multi-fold elevation in growth hormone persisting for several days, with a corresponding rise in IGF-1. That is a real finding about what the compound does to a biomarker.
For ipamorelin, individual pharmacology has also been characterised in human studies.
For the combination, no published randomised controlled trial exists. Not a small one, not an equivocal one. The specific pairing that is prescribed and marketed constantly has not been tested against placebo in a published trial.
And there is a further distinction that matters more than the first. Everything above concerns growth hormone and IGF-1 levels. Those are biomarkers. The claims typically attached to these compounds — improved body composition, better sleep, faster recovery, enhanced healing — are clinical outcomes. Demonstrating that a compound raises a biomarker is not the same as demonstrating it produces a clinical outcome, and the history of pharmacology contains many compounds that did the first reliably and the second not at all.
This is not an argument that the compounds do nothing. It is a description of what has and has not been shown.
The regulatory picture, honestly
Here I have to be candid about the limits of what can be stated.
In late 2023 the FDA placed a group of peptides, including CJC-1295 and ipamorelin, into Category 2 of the 503A bulk drug substances list. Under Section 503A, a Category 2 designation effectively means a substance should not be compounded, on the basis of identified safety concerns.
What has happened since is genuinely difficult to state with confidence from secondary sources. Reporting through 2026 is contradictory: some sources describe CJC-1295 as having been removed from Category 2 in April 2026 following withdrawal of its nomination, while others state that both compounds remained on Category 2 after the July 2026 advisory committee meeting. These accounts cannot all be correct.
What can be stated with confidence is narrower and still useful. Neither CJC-1295 nor ipamorelin was on the agenda for the Pharmacy Compounding Advisory Committee meeting of July 23 to 24, 2026. That meeting reviewed BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, and Epitalon. So whatever favourable committee recommendations came out of that meeting, they did not apply to these two compounds.
It can also be stated that neither is an FDA-approved medication, and that removal from a restricted list, a committee recommendation, and drug approval are three different things that are routinely conflated in coverage of this topic.
The practical conclusion: do not rely on this article, or any article, for the current status. Ask your provider to verify it against the FDA’s published list directly, on the day it matters.
What to actually ask
If you are considering this therapy, these questions separate a serious clinical relationship from a transactional one.
Which form of CJC-1295 is this, with or without DAC? A provider who cannot answer immediately is not attending to a meaningful pharmacological difference.
What is the current regulatory status, verified against the FDA list today? Not against a blog post, and not against what was true last year.
Where is it compounded, and can I see a certificate of analysis for my batch? Potency, sterility, and endotoxin testing are what distinguish a pharmaceutical preparation from an unregulated one. For an injectable, this is not a formality.
What outcome are we treating, and how will we measure it? If the answer is a biomarker, ask what clinical change that biomarker is expected to produce and on what basis.
What is the monitoring plan? IGF-1 and glucose handling are the obvious candidates given the mechanism. Therapy without monitoring is not therapy.
What would make us stop? A defined endpoint, or a defined failure condition.
A word on research-use products
These compounds are widely sold online under research-use-only labelling. That labelling is a legal position taken by the seller, stating that the product has not been prepared for human use. It should be read as exactly that.
Such products are not manufactured to pharmaceutical standards and may not undergo stability, potency, or endotoxin testing. Endotoxin contamination in an injectable is a concrete hazard, not a theoretical one. Anyone treating the disclaimer as a formality has inverted its meaning.
Where I land
The mechanism is real and the pharmacology is genuinely interesting. The human evidence for the combination, at the level of clinical outcomes rather than biomarkers, does not currently exist in published randomised form. The regulatory position is unsettled enough that I cannot responsibly summarise it in an article that will still be online in six months.
If someone chooses to pursue this with a physician who is honest about all three of those points, sources properly, and monitors appropriately, that is a defensible decision made with open eyes.
If it is presented to you as established, proven, or routine, the presentation is not accurate, and that tells you something useful about the source.
Neither CJC-1295 nor ipamorelin is an FDA-approved medication. Regulatory status changes and should be verified directly with the FDA at the time of any decision. This article is general education and does not constitute medical advice.